Industries > Pharma > Global Human Microbiome Therapeutics Market Forecast 2020-2030

Global Human Microbiome Therapeutics Market Forecast 2020-2030

Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, Dermatological Conditions, Other Disorders

PUBLISHED: 29 November 2019
PAGES: 345
PRODUCT CODE: PHA0622
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0622 Categories: , Tags: ,

The global human microbiome therapeutics market is estimated to grow at a CAGR of 80.2% in the first half of the forecast period. The global human microbiome therapeutics market is estimated to reach $1.6bn in 2025.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 345-page report you will receive 150 tables and 78 figures– all unavailable elsewhere.

The 345-page report provides clear detailed insight into the global human microbiome therapeutics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Human Microbiome Therapeutics Market forecast from 2020-2030

• Global Human Microbiome Therapeutics Market revenue forecast 2020-2030 by Sector:
• Gastrointestinal Disorders
• Infectious Diseases
• Metabolic Diseases
• Dermatological Conditions
• Other Disorders

• Global Human Microbiome Therapeutics Market revenue forecast 2020-2030 by Region:
• U.S.
• EU5: Germany, France, U.K., Italy, Spain
• APAC: Japan, China, India, Australia, Korea
• Rest of the World

Global Human Microbiome Therapeutics Market Forecast 2020-2030

The human microbiome market revenue forecast 2019-2029 for the US, EU5 and APAC markets are further broken down by sector.

• This report discusses the top 20 companies in the human microbiome therapeutics market:
• 4D Pharma
• AOBiome Therapeutics
• C3J Therapeutics
• Caelus Health
• Enterome Bioscience
• Ferring Pharmaceuticals
• Finch Therapeutics/Crestovo
• IGEN BIOTECH GROUP
• Immuron
• Intrexon Corporation
• MaaT Pharma
• MatriSys Biosystem
• Microbiome Therapeutics LLC
• Osel
• Ritter Pharmaceuticals
• Second Genome
• Seres Therapeutics
• Synlogic
• Synthetic Biologics
• Vedanta Biosciences

This report discusses collaborations and acquisition, recent developments, drugs developments and key pipeline products

• This report lists and discusses the main pipeline products in these main sectors: gastrointestinal disorders submarket, metabolic disorders submarket, infectious diseases submarket, dermatological disorders submarket and other disorders submarket.

• Qualitative analysis of the human microbiome therapeutics market in the form of a SWOT Analysis.

• Key Questions Answered by this Report:
• How is the market for human microbiome therapeutics evolving?
• What is driving and restraining the human microbiome therapeutics market dynamics?
• What are the market shares of the submarkets for gastrointestinal disorders, infectious diseases, metabolic diseases, dermatological conditions, and other disorders from the overall human microbiome therapeutics market?
• How will each of the submarket segments within the human microbiome therapeutics market grow over the forecast period and how much revenue will these submarkets account for in 2030?
• How will the market shares for each of the submarkets within the human microbiome therapeutics market develop from 2020 to 2030?
• Which submarkets will be the main driver of growth in the overall market from 2020 to 2030?
• How will the regional market shares in the human microbiome therapeutics market change by 2030 and which geographical region will lead the market in 2030?

Visiongain’s study is intended for anyone requiring commercial analyses for the global human microbiome therapeutics market. You find data, trends and predictions.

Buy our report today Global Human Microbiome Therapeutics Market Forecast 2020-2030: Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, Dermatological Conditions, Other Disorders.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Global Human Microbiome Therapeutics Market Forecast 2020-2030


Download sample pages

Complete the form below to download your free sample pages for Global Human Microbiome Therapeutics Market Forecast 2020-2030


Latest Pharma news

“Global Vaccine Contract Manufacturing market set to grow to $3,831.7m by 2025” says new Visiongain report

Major fluctuations in demand are seen in the case of influenza, as was seen during pandemics over the last decade. Unexpectedly, the Coronavirus or COVID-19 outbreak that started from Wuhan, China, has spread across continents, affecting various industries globally.

08 April 2020

READ

Visiongain’s analysis indicates that total revenue on Tuberculosis Treatment Drugs Market will be $1,080 million in 2020 due to the World Health Organization strong commitment towards ending TB leading to increase in funding for the research and development both in developed as well and under-developed markets

Due to maturity of generic drug market, companies are moving away from generics drug into therapeutic market by building strong portfolio for development of anti-tuberculosis drug emphasizing all types of TB cases.

06 April 2020

READ

The Global Wound Care Market Is Set to Boom, Particularly in Emerging Economies

The global wound care market is big, and only set to grow bigger.  Currently, estimates show a CAGR of 4.6% in the years to come, with the overall market growing from US$19.8 billion in 2019 to US$24.8 billion by 2024.  The industry is ripe with opportunity, with that growth coming from several factors – but most especially growth in emerging …

30 March 2020

READ

“The global nasal drug delivery technology market is estimated to have reached $44,385 million in 2019” says new Visiongain report

Nasal Sprays segment held the largest market share of the global nasal drug delivery technology market in 2019.

30 March 2020

READ

Categories

Category